CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
Loredana Amoroso, Giovanni Erminio, Guy Makin, Andrew D. J. Pearson, Penelope Brock, Dominique Valteau-Couanet, Victoria Castel, Marlène Pasquet, Genevieve Laureys, Caroline Thomas, Roberto Luksch, Ruth Ladenstein, Riccardo Haupt, Alberto Garaventa,
Cancer Research and Treatment. 2018;50(1):148-155.   Published online 2017 March 21    DOI: https://doi.org/10.4143/crt.2016.511

Excel Download

Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
Cancer Research and Treatment. 2018;50(1):148-155   Crossref logo
Link1 Link2 Link3

Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma
Cancer. 2010;116(12):3054-3060   Crossref logo
Link1 Link2

A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma
Cancer. 2003;98(11):2488-2494   Crossref logo
Link1 Link2

102 INVITED Recent Advancements for High Risk Neuroblastoma (HRN) in Europe Through the SIOP Europe Neuroblastoma Group (SIOPEN)
European Journal of Cancer. 2011;47:S26   Crossref logo
Link1 Link2

Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study
Cancers. 2019;11(10):1476   Crossref logo
Link1

Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study
Yearbook of Oncology. 2012;2012:219-220   Crossref logo
Link1 Link2

Erratum: Milano GM, Cozza R, Ilari I, et al. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk ewing sarcoma family tumors: The Bambino Gesù Children's Hospital experience.Cancer. 2006;106(8):1838–45.
Cancer. 2006;107(6):1421-1421   Crossref logo
Link1 Link2

Pharmacoeconomic Analysis of Pegylated Liposomal Doxorubicin Versus Doxorubicin In Patients with Metastatic Breast Cancer at High Risk of Cardiac Events
Value in Health. 2016;19(7):A731-A732   Crossref logo
Link1 Link2

A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer
Lung Cancer. 1993;10(3-4):277   Crossref logo
Link1 Link2

Response to Paclitaxel, Topotecan, and Topotecan-Cyclophosphamide in Children With Untreated Disseminated Neuroblastoma Treated in an Upfront Phase II Investigational Window: A Pediatric Oncology Group Study
Yearbook of Oncology. 2006;2006:333-334   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.